Ozempic (semaglutide) is approved for the treatment of type 2 diabetes (T2D) in the USA, EU, Canada, Japan, and Australia
New England Journal of Medicine, 382 (22), 21172128
Front view 12-week program Side profile 12-week program Back view 12-week program Small practice by design
Patients considering these medications should understand they are being used off-label for this indication, and expectations should be carefully managed regarding potential benefits and limitations
Maintaining weight loss after tirzepatide requires deliberate strategies: established exercise habits, protein-prioritized nutrition, and in some cases, transitioning to a lower maintenance dose rather than stopping completely
Related Articles Retatrutide Nausea: Rates, Timeline & Management Retatrutide nausea affects 25-48% of users